Fennec Pharmaceuticals (FENC) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.98, -3.57% vs the prior close of $10.35.
- Volume 129.97K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
FENC slides 3.6% to $9.98. Closed at $9.98, -3.57% vs the prior close of $10.35. Day range $9.87–$10.35, opened at $10.32.
FENC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — FENC slides 3.6% to $9.98
- Closed at $9.98, -3.57% vs the prior close of $10.35. Day range $9.87–$10.35, opened at $10.32.
- Volume was 129.97K shares, 0.6x its 50-day average of 207.99K.
- Price is -10.9% vs its 50-day average ($11.20) and +10.1% vs its 200-day average ($9.06).
- 52-week range $5.65–$13.25; today's close sits at 57% of that range, 24.7% below the 52-week high.
Oct 15, 2026 — FENC jumps 3.7% to $10.35
- Closed at $10.35, +3.71% vs the prior close of $9.98. Day range $9.88–$10.47, opened at $9.98.
- Volume was 112.10K shares, 0.5x its 50-day average of 208.82K — lighter than usual.
- Price is -7.8% vs its 50-day average ($11.22) and +14.3% vs its 200-day average ($9.05).
- 52-week range $5.65–$13.25; today's close sits at 62% of that range, 21.9% below the 52-week high.
Oct 14, 2026 — FENC dips 2.0% to $9.98, a 1-month low
- Closed at $9.98, -1.96% vs the prior close of $10.18. Day range $9.92–$10.31, opened at $10.10.
- Volume was 207.60K shares, 1.0x its 50-day average of 208.00K.
- Price is -11.1% vs its 50-day average ($11.22) and +10.4% vs its 200-day average ($9.04).
- 52-week range $5.65–$13.25; today's close sits at 57% of that range, 24.7% below the 52-week high.
Oct 13, 2026 — FENC slides 5.0% to $10.18, a 1-month low
- Closed at $10.18, -5.04% vs the prior close of $10.72. Day range $10.09–$10.75, opened at $10.72.
- Volume was 231.60K shares, 1.1x its 50-day average of 205.72K.
- Price is -9.3% vs its 50-day average ($11.23) and +12.7% vs its 200-day average ($9.03).
- 52-week range $5.65–$13.25; today's close sits at 60% of that range, 23.2% below the 52-week high.
Oct 12, 2026 — FENC ends flat (+0.1%) to $10.72, 4 up days in a row
- Closed at $10.72, +0.09% vs the prior close of $10.71. Day range $10.42–$10.83, opened at $10.68.
- Volume was 90.10K shares, 0.4x its 50-day average of 205.66K — lighter than usual.
- Price is -4.4% vs its 50-day average ($11.22) and +18.9% vs its 200-day average ($9.02).
- 52-week range $5.65–$13.25; today's close sits at 67% of that range, 19.1% below the 52-week high.
- That makes 4 straight gains.
Oct 9, 2026 — FENC rises 0.8% to $10.71, 3 up days in a row
- Closed at $10.71, +0.75% vs the prior close of $10.63. Day range $10.57–$10.86, opened at $10.66.
- Volume was 93.20K shares, 0.5x its 50-day average of 205.60K — lighter than usual.
- Price is -4.3% vs its 50-day average ($11.19) and +19.0% vs its 200-day average ($9.00).
- 52-week range $5.65–$13.25; today's close sits at 67% of that range, 19.2% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — FENC rises 2.6% to $10.63
- Closed at $10.63, +2.61% vs the prior close of $10.36. Day range $10.24–$10.69, opened at $10.27.
- Volume was 87.20K shares, 0.4x its 50-day average of 205.87K — lighter than usual.
- Price is -4.9% vs its 50-day average ($11.18) and +18.3% vs its 200-day average ($8.99).
- 52-week range $5.65–$13.25; today's close sits at 66% of that range, 19.8% below the 52-week high.
Oct 7, 2026 — FENC ends flat (+0.1%) to $10.36
- Closed at $10.36, +0.10% vs the prior close of $10.35. Day range $10.08–$10.66, opened at $10.21.
- Volume was 130.80K shares, 0.6x its 50-day average of 204.91K.
- Price is -7.1% vs its 50-day average ($11.16) and +15.5% vs its 200-day average ($8.97).
- 52-week range $5.65–$13.25; today's close sits at 62% of that range, 21.8% below the 52-week high.
Oct 6, 2026 — FENC dips 2.5% to $10.35
- Closed at $10.35, -2.54% vs the prior close of $10.62. Day range $10.15–$10.66, opened at $10.64.
- Volume was 99.10K shares, 0.5x its 50-day average of 205.24K — lighter than usual.
- Price is -7.2% vs its 50-day average ($11.15) and +15.5% vs its 200-day average ($8.96).
- 52-week range $5.65–$13.25; today's close sits at 62% of that range, 21.9% below the 52-week high.
Oct 5, 2026 — FENC jumps 4.1% to $10.62
- Closed at $10.62, +4.12% vs the prior close of $10.20. Day range $10.01–$10.65, opened at $10.18.
- Volume was 118.00K shares, 0.6x its 50-day average of 204.68K — lighter than usual.
- Price is -4.7% vs its 50-day average ($11.15) and +18.7% vs its 200-day average ($8.94).
- 52-week range $5.65–$13.25; today's close sits at 65% of that range, 19.8% below the 52-week high.
Oct 2, 2026 — FENC dips 1.3% to $10.20, a 1-month low, 4 down days in a row
- Closed at $10.20, -1.26% vs the prior close of $10.33. Day range $10.03–$10.49, opened at $10.46.
- Volume was 136.40K shares, 0.7x its 50-day average of 204.27K.
- Price is -8.4% vs its 50-day average ($11.13) and +14.2% vs its 200-day average ($8.93).
- 52-week range $5.65–$13.25; today's close sits at 60% of that range, 23.0% below the 52-week high.
- That makes 4 straight losses.
FENC latest news & SEC filings
Every SEC filing by or about FENC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sayad Pierre Sargis received an award of 3,846 shares at $5.53 (≈$21.27K) on Oct 12, 2026; now holds 13,533
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hackman Jeffrey S. received an award of 2,224 shares at $5.53 (≈$12.30K) on Oct 12, 2026; now holds 69,685
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Evans Terry L received an award of 2,326 shares at $5.53 (≈$12.86K) on Oct 12, 2026; now holds 24,013
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cioffi Christiana Marie received an award of 3,946 shares at $5.53 (≈$21.82K) on Oct 12, 2026; now holds 28,746
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Andrade Robert received an award of 3,846 shares at $5.53 (≈$21.27K) on Oct 12, 2026; now holds 246,855
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sayad Pierre Sargis received an award of 168 shares on Sep 30, 2026; now holds 9,687
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $17.87M (prior year $9.65M) (+85.2% vs Jun 30, 2025)
- Net income: $1.97M (prior year -$3.15M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.05 (prior year -$0.11) (swung to profit vs Jun 30, 2025)
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade FENC
- Last results release: Mar 24, 2026 (8-K Item 2.02). Previous ones: Mar 10, 2025, Mar 25, 2024, Nov 7, 2023. Based on that rhythm, the next report is likely around Jun 23, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.21% (largest 5.0%).
- Liquidity: about 130.89K shares (≈$1.31M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $9.98 vs a range of $5.65–$13.25 (57% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Marco Maria Brughera sold 15,545 shares on Sep 15, 2026.
- Latest filings: 8-K Sep 17, 2026; 10-Q Aug 13, 2026; 8-K Jun 10, 2026.
- Share count: 35.07M shares outstanding (Aug 11, 2026), +26.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
FENC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.32 | 10.35 | 9.87 | 9.98 | 129.97K |
| Oct 15, 2026 | 9.98 | 10.47 | 9.88 | 10.35 | 112.10K |
| Oct 14, 2026 | 10.10 | 10.31 | 9.92 | 9.98 | 207.60K |
| Oct 13, 2026 | 10.72 | 10.75 | 10.09 | 10.18 | 231.60K |
| Oct 12, 2026 | 10.68 | 10.83 | 10.42 | 10.72 | 90.10K |
| Oct 9, 2026 | 10.66 | 10.86 | 10.57 | 10.71 | 93.20K |
| Oct 8, 2026 | 10.27 | 10.69 | 10.24 | 10.63 | 87.20K |
| Oct 7, 2026 | 10.21 | 10.66 | 10.08 | 10.36 | 130.80K |
| Oct 6, 2026 | 10.64 | 10.66 | 10.15 | 10.35 | 99.10K |
| Oct 5, 2026 | 10.18 | 10.65 | 10.01 | 10.62 | 118.00K |
| Oct 2, 2026 | 10.46 | 10.49 | 10.03 | 10.20 | 136.40K |
| Oct 1, 2026 | 10.58 | 10.65 | 10.14 | 10.33 | 130.10K |
| Sep 30, 2026 | 10.81 | 10.83 | 10.41 | 10.65 | 149.20K |
| Sep 29, 2026 | 10.99 | 11.11 | 10.64 | 10.80 | 117.70K |
| Sep 28, 2026 | 10.54 | 11.06 | 10.07 | 10.95 | 210.20K |
| Sep 25, 2026 | 10.53 | 10.81 | 10.51 | 10.60 | 105.10K |
| Sep 24, 2026 | 10.41 | 10.63 | 10.21 | 10.62 | 103.20K |
| Sep 23, 2026 | 11.01 | 11.01 | 10.50 | 10.51 | 141.60K |
| Sep 22, 2026 | 11.00 | 11.31 | 10.85 | 11.01 | 91.70K |
| Sep 21, 2026 | 10.63 | 10.94 | 10.43 | 10.91 | 132.90K |
About Fennec Pharmaceuticals
Fennec Pharmaceuticals (FENC) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in RESEARCH TRIANGLE PARK, NC. State of incorporation: British Columbia, Canada. Fiscal year ends December 31. SEC CIK 1211583.
FENC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Marco Maria Brughera | Director | Sep 16, 2026 |
| Jodi A Cook | Director | Jun 10, 2026 |
| Jeffrey S. Hackman | Chief Executive Officer | Aug 31, 2026 |
| Khalid Islam | Director | Jun 10, 2026 |
| Chris A Rallis | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert Andrade | CHIEF FINANCIAL OFFICER | Aug 31, 2026 |
| Christiana Marie Cioffi | Chief Strategy Officer | Aug 31, 2026 |
| Terry L Evans | Chief Commercial Officer | Aug 31, 2026 |
| Jeffrey S. Hackman | Chief Executive Officer | Aug 31, 2026 |
| Pierre Sargis Sayad | Chief Medical Officer | Aug 31, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Marco Maria Brughera | Sale | 15,545 | $10.29 |
| Sep 15, 2026 | Marco Maria Brughera | Sale | 15,545 | $10.29 |
| Sep 15, 2026 | Marco Maria Brughera | Sale | 15,545 | $10.29 |
| Sep 15, 2026 | Marco Maria Brughera | Sale | 15,545 | $10.29 |
| Sep 1, 2026 | Rosty Raykov | Sale | 10,000 | $12.11 |
| Sep 1, 2026 | Rosty Raykov | Sale | 10,000 | $12.11 |
| Sep 1, 2026 | Rosty Raykov | Sale | 10,000 | $12.11 |
| Sep 1, 2026 | Rosty Raykov | Sale | 10,000 | $12.11 |
| Aug 31, 2026 | Pierre Sargis Sayad | Sale | 12,000 | $12.18 |
| Aug 31, 2026 | Pierre Sargis Sayad | Sale | 12,000 | $12.18 |
| Aug 31, 2026 | Pierre Sargis Sayad | Sale | 12,000 | $12.18 |
| Aug 31, 2026 | Pierre Sargis Sayad | Sale | 12,000 | $12.18 |
| Aug 27, 2026 | Robert Andrade | Sale | 75,000 | $11.78 |
| Aug 27, 2026 | Robert Andrade | Sale | 75,000 | $11.78 |
| Aug 27, 2026 | Robert Andrade | Sale | 75,000 | $11.78 |
FENC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $44.64M | $-9.74M | -0.34 | $-12.47M |
| Dec 31, 2024 | $47.54M | $-436.00K | -0.02 | $26.98M |
| Dec 31, 2023 | $21.25M | $-16.05M | -0.60 | $-17.14M |
| Dec 31, 2022 | $1.53M | $-23.71M | -0.90 | $-18.06M |
| Dec 31, 2021 | — | $-17.35M | -0.67 | $-14.22M |
Latest balance sheet: total assets $75.75M, total liabilities $33.31M, cash $41.25M (as of Jun 30, 2026).
FENC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 24, 2026 | 8-K Item 2.02 (results) | $6.02 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $6.11 |
| Mar 25, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
| Aug 4, 2023 | 8-K Item 2.02 (results) | — |
| Feb 14, 2020 | 8-K Item 2.02 (results) | — |
| Nov 12, 2019 | 8-K Item 2.02 (results) | — |
| Aug 9, 2019 | 8-K Item 2.02 (results) | — |
| May 9, 2019 | 8-K Item 2.02 (results) | — |
| Mar 14, 2019 | 8-K Item 2.02 (results) | — |
| Aug 16, 2010 | 8-K Item 2.02 (results) | — |
| May 13, 2008 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on FENC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.